

Valentina Di iorio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4971812/publications.pdf>

Version: 2024-02-01

16
papers

364
citations

933447

10
h-index

940533

16
g-index

16
all docs

16
docs citations

16
times ranked

544
citing authors

#	ARTICLE	IF	CITATIONS
1	Theragnostic in neuroendocrine tumors. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2022, 65, .	0.7	2
2	Production and Quality Control of [177Lu]Lu-PSMA-I&T: Development of an Investigational Medicinal Product Dossier for Clinical Trials. Molecules, 2022, 27, 4143.	3.8	7
3	177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 152-160.	6.4	20
4	Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3260-3267.	6.4	29
5	Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial. British Journal of Cancer, 2021, 125, 1226-1232.	6.4	13
6	SUV95th as a Reliable Alternative to SUVmax for Determining Renal Uptake in [68Ga] PSMA PET/CT. Molecular Imaging and Biology, 2020, 22, 1070-1077.	2.6	4
7	68Ga-PSMA-11 PET/CT-Guided Stereotactic Body Radiation Therapy Retreatment in Prostate Cancer Patients with PSA Failure after Salvage Radiotherapy. Biomedicines, 2020, 8, 536.	3.2	11
8	Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of 225Ac-PSMA (Prostate-Specific Membrane Antigen). Frontiers in Oncology, 2020, 10, 531660.	2.8	15
9	Pembrolizumab in a Patient With Heavily Pre-Treated Squamous Cell Thymic Carcinoma and Cardiac Impairment: A Case Report and Literature Review. Frontiers in Oncology, 2020, 10, 1478.	2.8	7
10	Dosimetry and safety of 177Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 3008-3017.	6.4	37
11	A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods. Journal of Visualized Experiments, 2020, .	0.3	8
12	Dosimetry of 177Lu-PSMA-617 after Mannitol Infusion and Glutamate Tablet Administration: Preliminary Results of EUDRACT/RSO 2016-002732-32 IRST Protocol. Molecules, 2019, 24, 621.	3.8	34
13	Reduction of 68Ga-PSMA renal uptake with mannitol infusion: preliminary results. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2189-2194.	6.4	30
14	Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR). Supportive Care in Cancer, 2017, 25, 111-117.	2.2	8
15	Peptide receptor radionuclide therapy with 177Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and 18F-FDG PET. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1040-1046.	6.4	77
16	Feasibility and utility of re-treatment with 177Lu-DOTATATE in GEP-NENs relapsed after treatment with 90Y-DOTATOC. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1955-1963.	6.4	62